Osteoarthritis Shoulder Clinical Trial
— EPMOfficial title:
Endogenous Pain Modulation in Patients With Shoulder Arthroplasty for Osteoarthritis
NCT number | NCT05861960 |
Other study ID # | 2019-005-M |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 4, 2024 |
Est. completion date | August 2025 |
Rationale: Although most patients experience significant pain relief after total shoulder arthroplasty (TSA), pain persists for some patients even after surgery. The endogenous pain system may be involved in persisting postoperative pain in total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients, but this has never been studies for TSA patients. Furthermore, psychological factors and coping strategies may also be of interest but have not yet been extensively studied in TSA patients. Objective: The primary objective is to explore whether central sensitization and/or abnormal CPM responses are present in (a subgroup of) patients who will receive shoulder arthroplasty for osteoarthritis, and whether shoulder arthroplasty produces change in these measures of the endogenous pain modulatory system. The secondary objective, in case patients with altered endogenous pain modulation are found, is to explore if change in pain over time, psychological factors and coping strategies differ between patients with and without altered pain modulation. Study design: An exploratory prospective observational cohort study. Study population: Patients (age 18 years or older) who are scheduled to undergo shoulder arthroplasty for osteoarthritis, at the Reinier Haga Orthopaedic Centre. Intervention (if applicable): Not applicable. Main study parameters/endpoints: The main study parameters are CPM and TS values at baseline and at 3 and 6 months after surgery, as well as the absence/presence of allodynia at baseline and at 3 and 6 months after surgery. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden of participation will consist of completing questionnaires at baseline and at three and six months after surgery. In addition, subjects will undergo psychophysical testing at 3 moments, which can lead to redness or a burning sensation of the skin during the first 24 hours after testing. The investigators do not expect any additional risks associated with participation. There is no direct benefit for the subjects.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | August 2025 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 yrs - Scheduled to undergo primary total shoulder arthroplasty (TSA) or reversed shoulder arthroplasty (RSA) for primary shoulder osteoarthritis or cuff tear arthropathy - American Society of Anesthesiologists score 1, 2 or 3 - Able to provide written informed consent Exclusion Criteria: - Regular use of anti-depressants or anti-epileptics for any purpose, including SNRIs and gabapentinoids - The presence of any chronic pain disorder other than osteoarthritis - Osteoarthritis in joints other than the affected shoulder, for which arthroplasty is/will be planned in the near future - Difficulty with or inability to perform psychophysical testing (eg. in case of cognitive or psychiatric disorders) - Difficulty with or inability to communicate with the investigators (eg. difficulty with the Dutch language, cognitive/memory disorders) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Reinier Haga Orthopedic Center | Zoetermeer |
Lead Sponsor | Collaborator |
---|---|
Reinier Haga Orthopedisch Centrum |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The number of complications | The complications after surgery | 3 months, 6 months | |
Other | Mean operating time | The operating time in mintues | During surgery | |
Other | Optimal/suboptimal positioning of the prothesis | The positioning of the prothesis categorized in optimal and suboptimal based on the regular x-rays. | Directly postoperatively | |
Primary | Percentage of patients with adequate conditioned pain modulation (CPM, CPM value > 10%) | The subjects will score pain perception during the stimuli using the electronic visual analogue scoring (eVAS) system. The eVAS is scored on a scale of 0 (no pain) to 10 (worst pain). | Before surgery | |
Primary | Percentage of patients with adequate conditioned pain modulation (CPM, CPM value > 10%) | The subjects will score pain perception during the stimuli using the electronic visual analogue scoring (eVAS) system. The eVAS is scored on a scale of 0 (no pain) to 10 (worst pain). | 3 months | |
Primary | Percentage of patients with adequate conditioned pain modulation (CPM, CPM value > 10%) | The subjects will score pain perception during the stimuli using the electronic visual analogue scoring (eVAS) system. The eVAS is scored on a scale of 0 (no pain) to 10 (worst pain). | 6 months | |
Primary | Percentage of patients with normal emporal summation (TS, TS value < 2 points) | Subjects will verbally rate their pain during the test using the numeric rating scale (NRS). This is a scale on 0 (no pain) to 10 (worst pain). | Before surgery | |
Primary | Percentage of patients with normal emporal summation (TS, TS value < 2 points) | Subjects will verbally rate their pain during the test using the numeric rating scale (NRS). This is a scale on 0 (no pain) to 10 (worst pain). | 3 months | |
Primary | Percentage of patients with normal emporal summation (TS, TS value < 2 points) | Subjects will verbally rate their pain during the test using the numeric rating scale (NRS). This is a scale on 0 (no pain) to 10 (worst pain). | 6 months | |
Secondary | Mean pain score (NRS) | Pain will be measured using the Numeric Rating Scal for pain (NRS). This is a scale on 0 (no pain) to 10 (worst pain). | Before surgery, 3 months, 6 months | |
Secondary | Pain catastrophizing | The Pain Catastrophizing Scale (PCS) is a 13-item questionnaire that assesses catastrophizing about pain. The total score ranges from 0-52. A score of 30 and higher indicates a clinically relevant level of catastrophizing. | Before surgery, 3 months, 6 months | |
Secondary | Coping strategies | The Brief COPE consists of 28 items, measuring 14 subscales. Each scale is measured by two items, with each item scoring form 1 to 4. Higher subscale scores indicate a higher use of that coping strategy. | Before surgery, 3 months, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Not yet recruiting |
NCT06032416 -
DenCT Shoulder Bone Quality Evaluation
|
N/A | |
Enrolling by invitation |
NCT05067543 -
Perform Humeral System Study
|
||
Completed |
NCT04641546 -
Effectiveness of Occupation-Based Intervention Compared With Therapeutic Exercise for Older Adults With Shoulder OA.
|
N/A | |
Recruiting |
NCT05868148 -
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
|
||
Completed |
NCT03431857 -
Multi Centre Study on TESS V2 Shoulder System
|
||
Recruiting |
NCT06078865 -
FX Shoulder Prospective Clinical Study
|
||
Recruiting |
NCT04929951 -
The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis
|
Phase 1 | |
Recruiting |
NCT04968405 -
Catalyst CSR Shoulder System for Semi or Total Shoulder Arthroplasty
|
N/A | |
Enrolling by invitation |
NCT05500066 -
AEQUALIS™ FLEX REVIVE™ Study (REVIVE)
|
||
Active, not recruiting |
NCT05002959 -
TESS V3 Modular Total Shoulder System PMCF
|
||
Recruiting |
NCT06077942 -
FX Shoulder Solutions Retrospective / Prospective Clinical Study
|
||
Active, not recruiting |
NCT06171542 -
Efficacy of a Single Image Guided Injection of CTM for Glenohumeral Arthritis
|
Phase 1 | |
Recruiting |
NCT05487274 -
TSA v RSA in Osteoarthritic Shoulders With Greater Than 15 Degrees of Retroversion
|
N/A |